Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty

Authors not listed

Longeveron Inc. · 2017

Abstract

This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-28 MST

Cite this

APA
Anonymous. (2017). A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty. <em>Longeveron Inc.</em>. https://clinicaltrials.gov/study/NCT03169231
Vancouver
Anonymous. A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty. Longeveron Inc.. 2017.
BibTeX
@misc{anon2017APhase, title = {A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty}, author = {Anonymous}, journal = {Longeveron Inc.}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings